← All indications
Mouth Neoplasms
Tumors or cancer of the MOUTH.
Subtype terms (6)
More specific conditions that are subtypes of Mouth Neoplasms in the MeSH hierarchy.
- Gingival Neoplasms
- Leukoplakia, Oral
11 drugs (9 approved, 2 experimental)
- Lip Neoplasms
4 drugs approved
- Palatal Neoplasms
- Salivary Gland Neoplasms
99 drugs (57 approved, 42 experimental)
- Tongue Neoplasms
53 drugs (30 approved, 23 experimental)
Drugs by status
Phase 4 trials (5)
Phase 3 trials (24)
Phase 2 trials (46)
- metronidazole
- fluorothymidine
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- 68ga-nota-ae105
- dacomitinib
- anlotinib
- aminolevulinic acid
- bmx-001
- bowman-birk inhibitor
- tadalafil
- valproic acid
- doxorubicin
- gemcitabine
- trametinib
- nivolumab
- ipatasertib
- ipilimumab
- sacituzumab govitecan
- sirolimus
- technetium tc-99m sulfur colloid kit
- calcitriol
- capecitabine
- cabozantinib
- methotrexate
- watercress juice
- sodium thiosulfate
- lovastatin
- recombinant adenoviral human p53 gene
- prednisolone
- chlorhexidine
- +16 more
Phase 1 trials (19)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (25)
- Astellas
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- Tzu Chi University
- Centre Jean Perrin
- Chang Gung University
- Changhua Christian Hospital
- Chimei Medical Center
- ECOG-ACRIN Cancer Research Group
- National Cheng Kung University
- NRG Oncology
- Fudan University
- Groupe Oncologie Radiotherapie Tete et Cou
- Taichung Veterans General Hospital
- Jiao Tong University
- François Rabelais University
- National Taiwan University
- Institut Gustave Roussy
- Sun Yat-Sen University
- University of Texas at Houston
- Viventia Biotech Inc.
- Government of Taiwan
- People's Liberation Army of China
- University of Lorraine
- Mackay Medical College
Organization Involved with Phase 2 Indications (40)
- Celgene
- Bristol-Myers Squibb
- AstraZeneca
- Merck
- Pfizer
- Sanofi
- IRX Therapeutics
- National Institutes of Health (NIH)
- National Institute of Dental and Craniofacial Research (NIDCR)
- Azienda USL 4 Prato
- University of Jena
- University of Arizona
- Harvard University
- Emory University
- Georgetown University
- University of Washington
- Instituto do Cancer do Estado de São Paulo
- Jawaharlal Nehru Medical College
- Ohio State University
- Stanford University
- University of Iowa
- University of Liverpool
- University of Louisville
- University of Toronto
- University of California, Irvine
- University of California, San Diego
- University of California, San Francisco
- Medical University of South Carolina
- Friedrich Schiller University
- University of Sao Paulo
- +10 more
Organization Involved with Phase 1 Indications (18)
- Kyowa Hakko Kirin
- Light Sciences Oncology
- Mirati Therapeutics Inc.
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Duke University
- Osaka University
- Sanford Health
- Sanford Research
- Rutgers University
- Free University of Amsterdam
- Department of Health and Human Services
- Clinical Study Support, Inc.
- Fiverings Co., Ltd.
- Rowan University
- Ono Pharmaceuticals
- TATA Trusts
- Indrayani Hospital and Cancer Institute
- Grant Medical Foundation Ruby hall Clinic
Organization Involved with Other Experimental Indications (3)